Neurocrine Biosciences, Inc.
NBIX
$155.80
$5.213.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 28.59% | 21.45% | 19.61% | 18.42% | 21.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.59% | 21.45% | 19.61% | 18.42% | 21.73% |
| Cost of Revenue | 26.97% | 39.56% | 37.80% | 38.90% | 39.61% |
| Gross Profit | 29.51% | 12.73% | 11.08% | 9.02% | 13.52% |
| SG&A Expenses | 16.78% | 16.48% | 23.57% | 21.33% | 15.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.46% | 26.53% | 29.78% | 28.83% | 25.51% |
| Operating Income | 54.85% | 6.50% | -8.09% | -10.67% | 9.57% |
| Income Before Tax | 101.09% | 45.14% | 20.51% | 17.95% | -0.79% |
| Income Tax Expenses | 67.64% | 56.74% | 47.83% | 66.02% | 60.08% |
| Earnings from Continuing Operations | 118.64% | 40.23% | 10.91% | 2.68% | -17.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 118.64% | 40.23% | 10.91% | 2.68% | -17.28% |
| EBIT | 54.85% | 6.50% | -8.09% | -10.67% | 9.57% |
| EBITDA | 52.22% | 6.70% | -7.12% | -9.56% | 10.35% |
| EPS Basic | 120.51% | 41.73% | 11.36% | 1.47% | -19.25% |
| Normalized Basic EPS | 48.99% | 6.60% | -6.53% | -8.60% | 10.45% |
| EPS Diluted | 119.92% | 41.52% | 11.91% | 1.96% | -18.85% |
| Normalized Diluted EPS | 48.98% | 6.72% | -5.88% | -7.91% | 10.97% |
| Average Basic Shares Outstanding | -0.70% | -0.92% | -0.50% | 0.73% | 2.01% |
| Average Diluted Shares Outstanding | -0.73% | -1.21% | -1.26% | -0.05% | 1.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |